PG
BMRN icon

PEAK6 Group’s BioMarin Pharmaceuticals BMRN Stock Holding History

PEAK6 Group’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		$170K Buy
+1,800
New +$158K ﹤0.01% 3441
2018
Q1 		– Sell
-64,200
Closed -$5.72M – 4340
2017
Q4 		$5.72M Buy
64,200
+12,700
+25% +$1.1M 0.03% 744
2017
Q3 		$4.79M Sell
51,500
-59,400
-54% -$5.25M 0.02% 775
2017
Q2 		$10.1M Buy
110,900
+91,000
+457% +$8.28M 0.06% 373
2017
Q1 		$1.75M Sell
19,900
-7,300
-27% -$649K 0.01% 1251
2016
Q4 		$2.25M Sell
27,200
-18,100
-40% -$1.56M 0.02% 1217
2016
Q3 		$4.19M Sell
45,300
-14,100
-24% -$1.33M 0.03% 795
2016
Q2 		$4.62M Sell
59,400
-78,200
-57% -$6.65M 0.04% 713
2016
Q1 		$11.3M Buy
137,600
+120,500
+705% +$9.8M 0.09% 277
2015
Q4 		$1.79M Buy
17,100
+6,800
+66% +$710K 0.01% 1437
2015
Q3 		$1.08M Sell
10,300
-12,900
-56% -$1.72M 0.01% 2119
2015
Q2 		$3.17M Sell
23,200
-41,300
-64% -$5.12M 0.02% 1140
2015
Q1 		$8.04M Sell
64,500
-21,200
-25% -$2.25M 0.06% 419
2014
Q4 		$7.75M Buy
85,700
+74,100
+639% +$6.16M 0.06% 418
2014
Q3 		$837K Sell
11,600
-8,300
-42% -$545K 0.01% 1979
2014
Q2 		$1.24M Buy
19,900
+16,900
+563% +$1.02M 0.01% 1459
2014
Q1 		$205K Sell
3,000
-62,100
-95% -$4.58M ﹤0.01% 3409
2013
Q4 		$4.58M Sell
65,100
-41,100
-39% -$2.79M 0.03% 790
2013
Q3 		$7.66M Buy
106,200
+61,200
+136% +$4.07M 0.05% 461
2013
Q2 		$2.51M Buy
+45,000
New +$2.8M 0.01% 1315

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

PEAK6 Group's BMRN Position: Q2 2018 in Review

PEAK6 Group reduced its BioMarin Pharmaceuticals (BMRN) stake by 25% in Q2 2018, selling an estimated $2.53M and leaving 87,517 shares worth $8.24M. The position accounts for 0.04% of the portfolio, ranked #533.

PEAK6 Group first reported a position in BMRN in Q2 2013 and has held it in 17 quarters since. The position peaked at $9.43M in Q1 2018. 449 funds tracked by Wall St. Rank hold BMRN as of Q2 2018.

  • PEAK6 Group held 87,517 shares of BioMarin Pharmaceuticals worth $8.24M as of Q2 2018.
  • PEAK6 Group sold 28,857 BioMarin Pharmaceuticals shares in Q2 2018, an estimated $2.53M.
  • BioMarin Pharmaceuticals made up 0.04% of PEAK6 Group's portfolio in Q2 2018, its #533 holding.
  • PEAK6 Group first reported a position in BioMarin Pharmaceuticals in Q2 2013 and has held it in 17 quarters since.
  • PEAK6 Group's BioMarin Pharmaceuticals position peaked at $9.43M in Q1 2018.
  • 449 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2018.

Based on PEAK6 Group's 13F filing for Q2 2018, filed 15 Aug 2018.